Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Veraxa Biotech AG - Ordinary Shares (NQ:VRXA)

2.010 +0.210 (+11.67%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Veraxa Biotech AG - Ordinary Shares

< Previous 1 2 Next >
MissionIRNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Approve Corporate Governance, Financing Measures
Via Investor Brand Network
BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration
Via Investor Brand Network
News headline image
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
VXA-222 advances into next phase at VERAXA 
From Veraxa Biotech AG
Via GlobeNewswire
News headline image
VERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth
From Veraxa Biotech AG
Via GlobeNewswire
NetworkNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Appoints Christoph Erkel as Chief Scientific Officer
Via Investor Brand Network
News headline image
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC® Technology Platforms and Portfolio
From Veraxa Biotech AG
Via GlobeNewswire
VERAXA Biotech AG (NASDAQ: VRXA) Advances BiTAC(R)-TCE Development with Positive Regulatory Feedback from Germany
Via Investor Brand Network
MissionIRNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform
Via Investor Brand Network
News headline image
VERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development Plan
Scientific Advice from the German Regulatory Authority supports the biological rationale and proposed development approach for VERAXA's BiTAC-TCE technology and product candidate, providing an initial... 
From Veraxa Biotech AG
Via GlobeNewswire
Why VERAXA Biotech AG (NASDAQ: VRXA) Could Benefit More Than Others From AI’s Growing Impact on Drug R&D
Via Investor Brand Network
Topics Artificial Intelligence
InvestorNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Partners With Ardigen to Advance AI-Driven Cancer Drug Development
Via Investor Brand Network
Topics Artificial Intelligence
NetworkNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Appoints Carl von Halem Interim Chief Financial Officer
Via Investor Brand Network
News headline image
VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline
Ardigen platform supports VERAXA’s in-house AI capabilities to optimize cancer target pair selection for conditionally active t cell engagers (TCEs) and antibody drug conjugates (ADCs) 
From Veraxa Biotech AG
Via GlobeNewswire
News headline image
VERAXA Biotech AG Appoints Carl von Halem as Interim Chief Financial Officer and Successor to Torsten Bürgermeister
From VERAXA Biotech GmbH
Via GlobeNewswire
VERAXA Biotech AG (NASDAQ: VRXA) Advances Lead BiTAC(R) T-Cell Engager Program with Cell Line Development Partnership
Via Investor Brand Network
MissionIRNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Should Watch Novartis Latest $1.5 Billion ADC Acquisition
Via Investor Brand Network
BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategy
Via Investor Brand Network
BillionDollarBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategy
Via Investor Brand Network
News headline image
VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines
Novel conditionally active T cell engagers sourced from proprietary BiTAC® platform are at the basis of advanced partnering initiatives and development activities 
From VERAXA Biotech GmbH
Via GlobeNewswire
BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program
Via Investor Brand Network
News headline image
VERAXA Biotech Initiates Cell Line Development with ATUM to Advance its Lead BiTAC®-TCE Program
ATUM, a leading US-based contract research organization, selected to support stable clonal cell line generation to advance VERAXA’s lead BiTAC-TCE program toward IND/CTA-enabling activities 
From VERAXA Biotech GmbH
Via GlobeNewswire
Why VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Should Pay Serious Attention to Antibody Therapeutics Sector Deals
Via Investor Brand Network
InvestorNewsBreaks – Xlife Sciences AG (SIX: XLS) Shareholders Approve All Annual Meeting Proposals
Via Investor Brand Network
VERAXA Biotech AG (NASDAQ: VRXA) Advances BiTAC-ADC Platform as It Expands Next-Generation Cancer Therapy Pipeline
Via Investor Brand Network
BillionDollarBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Expands Heidelberg R&D Facilities To Support Drug Development Pipeline
Via Investor Brand Network
News headline image
VERAXA Biotech Expands R&D Hub in Heidelberg as Innovative BiTAC™-TCE and ADC Programs Advance Towards Clinical Development
Greater than 60% increase in laboratory space will strengthen R&D capabilities, facilitate acceleration toward clinical development, and increase ability to tap into Heidelberg’s world-class medical... 
From VERAXA Biotech GmbH
Via GlobeNewswire
BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Showcases BiTAC Cancer Platforms Ahead of BIO International Convention
Via Investor Brand Network
MissionIRNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Showcases BiTAC Cancer Platforms Ahead of BIO International Convention
Via Investor Brand Network
BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Reports Proof-of-Concept Data for BiTAC-ADC Cancer Therapy Platform
Via Investor Brand Network
News headline image
VERAXA Biotech Establishes in vitro Proof-of-Concept for Novel BiTAC-ADC Technology Platform and Launches Partnering Discussions at BIO International Convention 2026
BiTAC-ADC in vitro data, along with initial data from the most advanced BiTAC-TCE program recently presented at the American Association for Cancer Research (AACR) Annual Meeting, underpin the... 
From VERAXA Biotech GmbH
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.